Repurposing of Idebenone as a potential anticancer agent

Elisabetta Damiani, Raif Yuecel, Heather M. Wallace (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain tumour associated with high rates of morbidity and mortality. In the present study, we considered the potential use of idebenone (IDE), a Coenzyme Q10 analogue, as a novel chemotherapeutic agent for GB. On two GB cell lines, U373MG and U87MG, IDE decreased the viable cell number and enhanced the cytotoxic effects of two known anti-proliferative agents: temozolomide and oxaliplatin. IDE also affected the clonogenic and migratory capacity of both GB cell lines, at 25 and 50 µM, a concentration equivalent to that transiently reached in plasma after oral intake that is deemed safe for humans. p21 protein expression was decreased in both cell lines, indicating that IDE likely exerts its effects through cell cycle dysregulation, and this was confirmed in U373MG cells only by flow cytometric cell cycle analysis which showed S-phase arrest. Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. No major decrease in caspase-3 expression was observed in U87MG cells nor apoptosis as observed by flow cytometry analysis. Overall, the present study demonstrates that IDE has potential as an anti-proliferative agent for GB by interfering with several features of glioma pathogenesis such as proliferation and migration, and hence might be a drug that could be repurposed for aiding cancer treatments. Furthermore, the synergistic combinations of IDE with other agents aimed at different pathways involved in this type of cancer are promising.

Original languageEnglish
Pages (from-to)245-259
Number of pages15
JournalBiochemical Journal
Volume476
Issue number2
Early online date25 Jan 2019
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Antineoplastic Agents
Glioblastoma
Cells
oxaliplatin
coenzyme Q10
temozolomide
Cell Line
Caspase 3
Cell Cycle
Apoptosis
Oncology
Flow cytometry
Propidium
Annexin A5
idebenone
S Phase
Brain Neoplasms
Glioma
Tumors
Brain

Keywords

  • Idebenone
  • glioblastoma cells
  • anti-proliferation
  • anti-migration
  • P21(WAF1)

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry
  • Cell Biology

Cite this

Repurposing of Idebenone as a potential anticancer agent. / Damiani, Elisabetta; Yuecel, Raif; Wallace, Heather M. (Corresponding Author).

In: Biochemical Journal, Vol. 476, No. 2, 01.2019, p. 245-259.

Research output: Contribution to journalArticle

@article{fee99ef057a44ce8ab56cf1abb2d78c0,
title = "Repurposing of Idebenone as a potential anticancer agent",
abstract = "Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain tumour associated with high rates of morbidity and mortality. In the present study, we considered the potential use of idebenone (IDE), a Coenzyme Q10 analogue, as a novel chemotherapeutic agent for GB. On two GB cell lines, U373MG and U87MG, IDE decreased the viable cell number and enhanced the cytotoxic effects of two known anti-proliferative agents: temozolomide and oxaliplatin. IDE also affected the clonogenic and migratory capacity of both GB cell lines, at 25 and 50 µM, a concentration equivalent to that transiently reached in plasma after oral intake that is deemed safe for humans. p21 protein expression was decreased in both cell lines, indicating that IDE likely exerts its effects through cell cycle dysregulation, and this was confirmed in U373MG cells only by flow cytometric cell cycle analysis which showed S-phase arrest. Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. No major decrease in caspase-3 expression was observed in U87MG cells nor apoptosis as observed by flow cytometry analysis. Overall, the present study demonstrates that IDE has potential as an anti-proliferative agent for GB by interfering with several features of glioma pathogenesis such as proliferation and migration, and hence might be a drug that could be repurposed for aiding cancer treatments. Furthermore, the synergistic combinations of IDE with other agents aimed at different pathways involved in this type of cancer are promising.",
keywords = "Idebenone, glioblastoma cells, anti-proliferation, anti-migration, P21(WAF1)",
author = "Elisabetta Damiani and Raif Yuecel and Wallace, {Heather M.}",
note = "Funding. E.D. was funded by an internal research grant from the Polytechnic University of the Marche provided by MIUR (Italian Ministry of University and Research). Funding for FACS experiments was provided by grant code no. RO10014-13 from the Cell, Developmental and Cancer Biology Research Programme, University of Aberdeen.",
year = "2019",
month = "1",
doi = "10.1042/BCJ20180384",
language = "English",
volume = "476",
pages = "245--259",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Repurposing of Idebenone as a potential anticancer agent

AU - Damiani, Elisabetta

AU - Yuecel, Raif

AU - Wallace, Heather M.

N1 - Funding. E.D. was funded by an internal research grant from the Polytechnic University of the Marche provided by MIUR (Italian Ministry of University and Research). Funding for FACS experiments was provided by grant code no. RO10014-13 from the Cell, Developmental and Cancer Biology Research Programme, University of Aberdeen.

PY - 2019/1

Y1 - 2019/1

N2 - Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain tumour associated with high rates of morbidity and mortality. In the present study, we considered the potential use of idebenone (IDE), a Coenzyme Q10 analogue, as a novel chemotherapeutic agent for GB. On two GB cell lines, U373MG and U87MG, IDE decreased the viable cell number and enhanced the cytotoxic effects of two known anti-proliferative agents: temozolomide and oxaliplatin. IDE also affected the clonogenic and migratory capacity of both GB cell lines, at 25 and 50 µM, a concentration equivalent to that transiently reached in plasma after oral intake that is deemed safe for humans. p21 protein expression was decreased in both cell lines, indicating that IDE likely exerts its effects through cell cycle dysregulation, and this was confirmed in U373MG cells only by flow cytometric cell cycle analysis which showed S-phase arrest. Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. No major decrease in caspase-3 expression was observed in U87MG cells nor apoptosis as observed by flow cytometry analysis. Overall, the present study demonstrates that IDE has potential as an anti-proliferative agent for GB by interfering with several features of glioma pathogenesis such as proliferation and migration, and hence might be a drug that could be repurposed for aiding cancer treatments. Furthermore, the synergistic combinations of IDE with other agents aimed at different pathways involved in this type of cancer are promising.

AB - Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain tumour associated with high rates of morbidity and mortality. In the present study, we considered the potential use of idebenone (IDE), a Coenzyme Q10 analogue, as a novel chemotherapeutic agent for GB. On two GB cell lines, U373MG and U87MG, IDE decreased the viable cell number and enhanced the cytotoxic effects of two known anti-proliferative agents: temozolomide and oxaliplatin. IDE also affected the clonogenic and migratory capacity of both GB cell lines, at 25 and 50 µM, a concentration equivalent to that transiently reached in plasma after oral intake that is deemed safe for humans. p21 protein expression was decreased in both cell lines, indicating that IDE likely exerts its effects through cell cycle dysregulation, and this was confirmed in U373MG cells only by flow cytometric cell cycle analysis which showed S-phase arrest. Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. No major decrease in caspase-3 expression was observed in U87MG cells nor apoptosis as observed by flow cytometry analysis. Overall, the present study demonstrates that IDE has potential as an anti-proliferative agent for GB by interfering with several features of glioma pathogenesis such as proliferation and migration, and hence might be a drug that could be repurposed for aiding cancer treatments. Furthermore, the synergistic combinations of IDE with other agents aimed at different pathways involved in this type of cancer are promising.

KW - Idebenone

KW - glioblastoma cells

KW - anti-proliferation

KW - anti-migration

KW - P21(WAF1)

UR - http://www.scopus.com/inward/record.url?scp=85060554776&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/repurposing-idebenone-potential-anticancer-agent

U2 - 10.1042/BCJ20180384

DO - 10.1042/BCJ20180384

M3 - Article

VL - 476

SP - 245

EP - 259

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 2

ER -